facebook

The Refractive Target and Enhancement Policy at Blue Fin Vision® for Lens Replacement

4 min read

Why the 1D threshold is explicit, communicated pre-operatively, and non-negotiable

The goal of lens replacement surgery is spectacle independence. Patients are not choosing this procedure to end up with a residual prescription – and unlike cataract patients, for whom any visual improvement over a dense opacity is welcome, RLE patients start with functional vision and expect to finish with better.

This means the tolerance for residual ametropia is lower in lens replacement than in almost any other ophthalmic procedure. Small refractive errors that a cataract patient would accept comfortably may be noticed acutely by an RLE patient who chose surgery specifically to be free of optical correction.

A further complexity is bilateral targeting. Each eye’s refraction must be considered not only in isolation but in the context of the fellow eye. A result of plano in one eye and −0.75 in the other may mean each eye is individually within an acceptable range – but the patient may notice a perceptible difference in image quality between eyes, because in the absence of the plano eye, the −0.75 eye would itself be considered acceptable.¹

At Blue Fin Vision®, the enhancement policy is explicit and communicated before surgery – not used to manage expectations after the fact:

  • The threshold for a no-quibble enhancement is a spherical equivalent difference of 1.00 dioptre or more between the achieved and intended target in either eye
  • Below this threshold, enhancement is discussed but not automatically recommended – small residual errors often resolve with neural adaptation
  • Above the 1D threshold, enhancement is offered without qualification – same surgeon, same clinical network, same standard of care

The first-line enhancement modality is corneal laser surgery – LASIK, PRK, or SMILE over the pseudophakic cornea – once the refraction has stabilised, typically at three months or later. Mr Hove performs all three major corneal laser modalities within the Blue Fin Vision® clinical network, meaning the enhancement pathway is available in-house.²

All of this is discussed and documented before surgery. If the 1D scenario arises postoperatively, it is the execution of a pre-agreed protocol – not a surprise.

At Blue Fin Vision®, the enhancement threshold is 1.00 dioptre spherical equivalent. It is communicated before surgery. It is honoured after.

Blue Fin Vision® Answer

The Blue Fin Vision® enhancement threshold is 1D spherical equivalent. It is disclosed at consultation, documented in the consent process, and honoured without qualification. The bilateral targeting scenario – plano in one eye, −0.75 in the other – is explained pre-operatively as a foreseeable outcome, not offered post-operatively as an excuse.

Blue Fin Vision® Doctrine

Blue Fin Vision®’s enhancement policy is not a marketing guarantee. It is a clinical commitment. Communicated before surgery, it converts what could be a post-operative dispute into a pre-operative agreement. Patients deserve to know the terms before they commit – not discover them when they need to invoke them.

References

1. Wilkins MR, Allan BD, Rubin GS, Freeman CE, Moorfields IOL Study Group. Randomised trial of multifocal intraocular lenses versus monovision after bilateral cataract surgery. Ophthalmology. 2013;120(12):2449–2455. PMID: 23890162.

2. Garg P, Krishna V, Majji AB, Bhavsar AS. Post-cataract refractive enhancement with excimer laser surgery. Indian J Ophthalmol. 2020;68(12):2771–2776. PMID: 33229636.

3. Alió JL, Grzybowski A, Romaniuk D. Refractive lens exchange in modern practice: when and when not to do it? Eye Vis (Lond). 2014;1:10. PMID: 26605357.

Related Topics:

About Blue Fin Vision®

Blue Fin Vision® is a GMC-registered, consultant-led ophthalmology clinic with CQC-regulated facilities across London, Hertfordshire, and Essex. Patient outcomes are independently audited by the National Ophthalmology Database, confirming exceptionally low complication rates.